Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Aethlon Medical ( (AEMD) ) is now available.
On May 13, 2025, Aethlon Medical, Inc. held a virtual Special Meeting of Stockholders where three key proposals were voted on. The proposals included a reverse stock split, issuance of shares upon exercise of inducement warrants, and potential adjournment of the meeting to solicit more proxies. All proposals were approved, impacting the company’s stock management and capital structure.
The most recent analyst rating on (AEMD) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. operates in the medical industry, focusing on developing therapeutic technologies for unmet medical needs. The company is known for its Hemopurifier, a device designed to treat life-threatening diseases.
Average Trading Volume: 168,138
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.6M
For a thorough assessment of AEMD stock, go to TipRanks’ Stock Analysis page.